Genetic variants in LKB1/AMPK/mTOR pathway are associated with clinical outcomes of chemotherapy in non‐small cell lung cancer

Genetic variants in LKB1/AMPK/mTOR pathway are associated with clinical outcomes of chemotherapy in non‐small cell lung cancer

Abstract This study was conducted to investigate the relationship between genetic variants in LKB1/AMPK/mTOR pathway and treatment outcomes of patients with non‐small cell lung cancer (NSCLC) treated with chemotherapy. A total of 379 patients with NSCLC who underwent first‐line paclitaxel‐cisplatin...

Full description

Bibliographic Details
Main Authors: Sun Ha Choi, Sook Kyung Do, Shin Yup Lee, Jin Eun Choi, Hyo‐Gyoung Kang, Mi Jeong Hong, Jang Hyuck Lee, Won Kee Lee, Ji Yun Jeong, Kyung Min Shin, Young Woo Do, Eung Bae Lee, Ji Eun Park, Yong Hoon Lee, Hyewon Seo, Seung Soo Yoo, Jaehee Lee, Seung Ick Cha, Chang Ho Kim, Jae Yong Park
Format: Article
Language:English
Published: Wiley 2022-12-01
Series:Thoracic Cancer
Subjects:
chemotherapy response
LKB1/AMPK/mTOR pathway
lung cancer
survival
variant
Online Access:https://doi.org/10.1111/1759-7714.14688

Internet

https://doi.org/10.1111/1759-7714.14688

Similar Items